# Cresco Labs Inc.: Form 40-F for the period ended Dec 31, 2024

- Company: [Cresco Labs Inc.](/companies/crlbf.md) (CIK 1832928)
- Form: 40-F
- Filed: 2025-03-14
- Accepted by EDGAR: Mar 14, 2025, 16:46 ET
- Period: 2024-12-31
- Accession: 0001832928-25-000006
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1832928/000183292825000006/crlbf-20241231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1832928/000183292825000006/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | $724.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | $359.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2024-01-01 to 2024-12-31 | $364.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months, 2024-01-01 to 2024-12-31 | $254.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2024-01-01 to 2024-12-31 | $107.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | $49.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | −$74.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2024-01-01 to 2024-12-31 | 345,474,155 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | $132.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | $19.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-12-31 | $137.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | $294.3m | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | $1.36bn | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | $94.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-12-31 | $967.2m | us-gaap:Liabilities |
| Long-term debt | at 2024-12-31 | $460.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-12-31 | $2.6m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2024-12-31 | $11.9m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2024-12-31 | $474.9m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1832928/000183292825000006/crlbf-20241231.htm

Filed Mar 14, 2025.
Source: SEC EDGAR, the filing index for accession 0001832928-25-000006. Last ingested by Listed: Nov 6, 2026, 12:03 ET. No prices; not investment advice.